Examkin

Question

Difficulty: HardGynecologic Infections

A 2929-year-old woman, gravida 22, para 11, at 2222 weeks gestation presents to the clinic with severe vulvovaginal itching and a thick, white vaginal discharge for the past 55 days. She reports no abdominal pain, fever, or urinary symptoms. Her pregnancy has been uncomplicated. One month ago, she had a similar episode of vaginal itching that she self-treated with an over-the-counter 33-day course of intravaginal miconazole. Her symptoms temporarily improved but have now returned and are more severe. Vital signs are within normal limits. Pelvic examination reveals significant vulvar erythema, excoriations, and a thick, adherent, "cottage cheese-like" vaginal discharge. The cervix is closed, and there is no cervical motion tenderness. Vaginal pH is 4.24.2. Wet mount examination with potassium hydroxide (KOH) preparation reveals branching pseudohyphae and budding yeast. Which of the following is the most appropriate next step in management?

  1. Intravaginal clotrimazole for 77 daysAnswer
  2. B
    Single-dose oral fluconazole
  3. C
    Oral fluconazole once daily for 33 days
  4. D
    Intravaginal boric acid for 1414 days
  5. E
    Oral metronidazole for 77 days

Answer

The most appropriate next step in management is a 77-day course of intravaginal clotrimazole.
The patient's presentation of severe vulvovaginal pruritus, thick "cottage cheese-like" discharge, normal vaginal pH (typically <4.5< 4.5), and pseudohyphae on potassium hydroxide (KOH) preparation confirms the diagnosis of vulvovaginal candidiasis (VVC). Management of VVC depends heavily on the patient's pregnancy status. In non-pregnant individuals, an uncomplicated episode is typically treated with a short 11- to 33-day course of topical azoles or a single dose of oral fluconazole. If symptoms are severe or refractory to topical therapy, the standard next step in a non-pregnant patient is systemic therapy with a multi-dose oral fluconazole regimen.

However, because this patient is pregnant, the treatment algorithm is tightly restricted. Systemic absorption of oral fluconazole has been strongly associated with an increased risk of spontaneous abortion and specific congenital malformations (e.g., tetralogy of Fallot, cleft palate, and skeletal abnormalities). Consequently, all oral azoles are strictly contraindicated throughout all trimesters of pregnancy. The Centers for Disease Control and Prevention (CDC) guidelines mandate that VVC in pregnant women be treated exclusively with topical azole therapies (e.g., clotrimazole, miconazole). Furthermore, because pregnant women possess higher levels of circulating estrogen (which increases vaginal glycogen content and promotes intense Candida overgrowth), achieving symptomatic relief often requires a longer duration of therapy. The standard recommendation is a continuous 77-day course of an intravaginal azole, which is highly effective and poses no known risks to the developing fetus.

Step-by-Step Solution

1
Identify the patient's diagnosis based on the clinical presentation and laboratory findings.
The patient has vulvovaginal candidiasis (VVC), evidenced by severe pruritus, thick white discharge, normal vaginal pH (4.24.2), and pseudohyphae on KOH prep.
Synthesizing the physical exam and wet mount findings is required to accurately distinguish VVC from bacterial vaginosis and trichomoniasis.
2
Evaluate the patient's physiological context and recent treatment history.
The patient is pregnant (2222 weeks gestation) and has recently failed a short 33-day course of topical antifungal therapy.
Pregnancy status and prior treatment failure are critical factors that drastically alter the standard therapeutic algorithm for VVC.
3
Determine the appropriate guideline-concordant pharmacotherapy that safely addresses a refractory or recurrent infection during pregnancy.
A 77-day course of a topical azole (e.g., intravaginal clotrimazole) is indicated. Systemic oral antifungals and alternative therapies like boric acid are contraindicated.
While non-pregnant patients with recurrent or refractory VVC would safely step up to oral fluconazole therapy, pregnant patients must strictly utilize extended topical azole regimens to avoid severe teratogenic risks.

Key Concept

Management of vulvovaginal candidiasis in pregnancy requires the exclusive use of topical azole therapies for an extended 77-day duration, as systemic oral fluconazole and intravaginal boric acid are strictly contraindicated due to significant teratogenic risks.
Rate this question

Topics

Gynecologic Infections

More questions from this topic